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Abstract
Background and objective: Different drugs, including hypnotics, may inﬂ uence the pharmacodynamic 
effects of neuromuscular blockers (NMB). The aim of this study was to evaluate the inﬂ uence of 
propofol and etomidate on cisatracurium-induced neuromuscular blockade.
Method: We included 60 patients, ASA I and II, undergoing elective surgery under general anesthesia 
in the study and randomly allocated them into two groups, according to their hypnotic drug: GI 
(propofol) and GII (etomidate). Patients received intramuscular (IM) midazolam (0.1 mg.kg-1) as 
premedication and we performed induction with propofol (2.5 mg.kg-1) or etomidate (0.3 mg.kg-1), 
preceded by fentanyl (250 mg) and followed by cisatracurium (0.1 mg.kg-1). The patients were 
ventilated with 100% oxygen until obtaining a reduction of 95% or more in the adductor pollicis 
response amplitude, with subsequent laryngoscopy and tracheal intubation. Neuromuscular function 
was monitored by acceleromyograhpy. We evaluated the onset of action of cisatracurium, tracheal 
intubation conditions, and hemodynamic repercussions.
Results: The mean time and standard deviations of cisatracurium onset were: GI (86.6 ± 14.3 s) 
and GII (116.9 ± 11.6 s), with a signiﬁ cant difference (p < 0, 0001). Intubation conditions were 
acceptable in 100% of GI and 53.3% of GII patients (p < 0.0001).
Conclusion: Induction of neuromuscular blockade with cisatracurium was faster, with better 
intubation conditions in patients receiving propofol compared to those receiving etomidate, 
without hemodynamic repercussions.
© 2013 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. 
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Introduction
The onset of action of a neuromuscular blocker (NMB) may 
be deﬁ ned as the interval between the end of its injection 
and maximum depression of a peripheral muscle response, 
with adductor pollicis the most frequently used in clinical 
practice 1. This time interval can be inﬂ uenced by factors, 
such as hypnotics and those associated with neuromuscular 
block monitoring (e.g., time to muscle stabilization, control, 
and frequency of stimulation used) 1-5. Among drugs used in 
anesthesia, some hypnotics have certain peculiarities and 
different mechanisms, with may interfere with muscle re-
laxation induced by nondepolarizing neuromuscular blockers 
(NDNMB) 5,6-8. Among benzylisoquinolinic neuromuscular 
blockers, cisatracurium has a highly selective afﬁ nity to the 
motor endplate, which may explain the absence of autonomic 
ganglion and vagal effects and the low potential for histamine 
release. Cisatracurium has a high neuromuscular blocking 
potency, which contributes to its slow onset of action 9. 
The aim of this study was to evaluate comparatively 
the inﬂ uence of propofol and etomidate on cisatracurium-
induced neuromuscular block. 
Method
Randomized clinical trials were conducted after approval 
by the Medical and Research Ethics Committee and signed 
informed consent. The study included female patients, 
physical status ASA I-II, scheduled for elective surgery under 
general anesthesia with tracheal intubation and mechanical 
ventilation. Exclusion criteria were patients with neuromus-
cular, renal or hepatic diseases, electrolyte and acid-basic 
changes, history of gastroesophageal reﬂ ux disease, use of 
drugs interacting with neuromuscular blockers, and those 
with indicative signs of difﬁ culty to perform the laryngoscopic 
and tracheal intubation maneuvers (Mallampati III and IV).
Sample size calculation was based on a previous study 
by Muñoz et al. 10 in which the times of rocuronium onset 
of action were 48.2 ± 1.85 and 51.2 ± 13.8 seconds with 
propofol and etomidate used respectively as hypnotic agents 
for induction of anesthesia, representing a percentage diffe-
rence of 6% between drug associations. Other authors 11 also 
reported 4.6 ± 0.3 minutes for the onset of cisatracurium 
(2ED95) in anesthesia with propofol used as hypnotic. There 
were no studies in the literature comparing the association of 
etomidate and cisatracurium; thus, we assumed an expected 
difference of 6%  by the criteria reported above. Considering 
a signiﬁ cance level of 5% and a test power of 80%, based 
on the parameters described above, the required size was 
calculated at n = 60.
Therefore, 30 subjects were included into two groups 
according to the hypnotic drug used for anesthesia induction 
using SAS 9.1 software: propofol (Group 1, n = 30) and eto-
midate (Group II, n = 30). In both groups, we administered 
cisatracurium (0.1 mg.kg-1) during 5 seconds, corresponding 
to two times the ED95. Premedication consisted of IM mida-
zolam (0.1 mg.kg-1), 30 minutes before anesthesia induction. 
In the operating room, a peripheral vein was catheterized 
for hydration and drug administration. Anesthesia induction 
was achieved with fentanyl (250 μg), followed by propofol 
(2.5 mg.kg-1) or etomidate (0.3 mg.kg-1) and cisatracurium 
(0.1 mg.kg-1). We used a mask with 100% oxygen to ventilate 
patients, performing laryngoscopic and tracheal intubation 
maneuvers after obtaining 95% reduction or more in the 
control response amplitude of the thumb adductor muscle.
We use the cardioscope in DII lead, pulse oximetry, 
capnography, and noninvasive blood pressure for conti-
nuous monitoring. Neuromuscular transmission monitor 
(Acceleromyograph – TOF-GUARD) was used for neuromuscu-
lar block evaluation. Before induction, supramaximal stimuli 
(0.1 Hz) were applied for ﬁ ve minutes to stabilize the control 
response, using surface electrodes on the wrist, in the ulnar 
nerve pathway. We placed an acceleration transducer (piezo-
electric) on the thumb distal phalanx of the monitored limb 
and a temperature sensor on the thenar region skin. During 
and after anesthetic induction, neuromuscular function was 
monitored continuously with isolated stimuli until achieving 
complete neuromuscular block. Adductor pollicis responses 
shown in bar graphs and digital numbers were stored on a 
memory card and subsequently reproduced in a compatible 
computer, previously programmed. Data tracings of muscular 
responses (Figure 1) showed: 1) hypnotic injection; 2) cisa-
tracurium injection; 3) cisatracurium onset time (tracheal 
intubation).
The evaluation included: 1) cisatracurium onset time 
(time interval [sec] between starting cisatracurium injection 
and obtaining ≥ 95% reduction in the amplitude response of 
adductor pollicis muscle); 2) clinical condition of tracheal in-
tubation according to the scores proposed by Viby-Mogensen 
et al. 2, considering the following variables: difﬁ cult la-
ryngoscopy (degree), vocal cords position, and reaction to 
tracheal tube insertion (Table 1) - intubation was considered 
acceptable when all variables were considered excellent 
or good and unacceptable when at least one variable was 
considered poor; 3) hemodynamic parameters (mean arterial 
pressure [MAP] and heart rate [HR]), measured immediately 
before anesthesia induction (T0), after anesthesia induction, 
before laryngoscopy and tracheal intubation (M1), and 1 
minute after intubation (M2).
We used Student’s t-test for statistical analysis of pa-
tients’ characteristics and neuromuscular blocker onset of 
action, Fisher’s exact test to evaluate tracheal intubation 
conditions and MANOVA and Mann-Whitney tests to assess 
hemodynamic parameters. A level of 5% (p < 0.05) was con-
sidered signiﬁ cant. The software used for analysis was SAS 
version 10.2.
Results
There was no signiﬁ cant difference between groups regarding 
age, weight, and ASA physical status (Table 2).
The time to onset action of cisatracurium was signiﬁ cantly 
lower (p < 0.0001) in Group I (86.6 ± 14.3 seconds) than in 
Group II (116.9 ± 11.6 seconds). 
Tracheal intubation clinical conditions were considered 
acceptable (excellent or good) in all patients in Group I 
and acceptable in 16 (53.3%) and unacceptable (poor) in 14 
(46.7%) patients in Group II, with a signiﬁ cant difference 
between groups (p < 0.0001). Laryngoscopy was considered 
excellent in all patients of both groups. Regarding vocal cords 
position and movement, all patients in Group I had excellent 
scores and one patient in Group II had a good score (open 
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Figure 1 Adductor Pollicis Response.
Group I  propofol (upper tracing); Group II - etomidate (lower 
tracing). 1 –hypnotic injection; 2 – cisatracurium injection; 
3 – cisatracurium onset of action (tracheal intubation time).
Table 1  Assessment of Tracheal Intubation Conditions.2
Variable Acceptable Unacceptable
Excellent Good Poor
Laryngoscopy Easy Reasonable Difﬁ cult
Vocal cords Open With motion Closed
Cough Absent Mild Vigorous
Acceptable: all variables are excellent or good; unacceptable: 
at least one of the variables is poor.
Table 2  Patients’ Demographic Characteristics.
Group I 
(propofol)
Group II p
Age (years)* 44.6 ± 7.1 43.6 ± 7.7 0.627
Weight (kg)* 62.9 ± 8.6 62.6 ± 5.6 0.684
Physical status (ASA 
I/II)**
20/10 20/10
* Data expressed as mean ±  SD; ** number of patients; 
Student’s t-test.
Table 3  Cardiovascular Parameters (Mean ±  SD).
MAP (mm Hg) HR (bpm)
M0 M1 M2 M0 M1 M2
Group I 86.0 ± 9.4 78.9 ± 9.6 83.8 ± 11.1 78.5 ± 11.8 74.8 ± 11.8 75.4 ± 10.2
Group II 83.5 ± 8.5 78.7 ± 7.6 86.4 ±  8.6 79.3 ± 13.0 75.0 ± 12.0 80.1 ± 13.4
p 0.13 0.92 0.17 0.78 0.93 0.13
MANOVA and Mann-Whitney tests.
vocal cord with movement). Vigorous cough occurred in 14 
patients in Group II and mild cough in ﬁ ve patients in Group I, 
with a signiﬁ cant difference between groups (p < 0.0001). 
Mean values  and standard deviations of cardiovascular 
parameters (MAP and HR) in both groups are shown in Table 3. 
There was signiﬁ cant difference between groups at different 
time points. In both groups, the changes in MAP and HR over 
time showed no signiﬁ cant difference (p = 0.98 and 0.50, 
respectively).
Discussion
In clinical practice, the desirable characteristics in selecting 
a neuromuscular blocker are hemodynamic stability, rapid 
onset of action, and ability to provide adequate muscle re-
laxation to enable laryngoscopy and tracheal intubation 11. 
Cisatracurium is one of the 10 isomers of atracurium, with 
ED95 of 0.05 mg.kg
-1 in balanced anesthesia, without car-
diovascular effects due to histamine release, which is an 
important advantage over atracurium 11,12. 
This study evaluated the onset of action, tracheal in-
tubation conditions, and hemodynamic repercussions of 
cisatracurium with a dose corresponding to two ED95, using 
propofol or etomidate as hypnotic agents during anesthesia 
induction, as installation of neuromuscular block and tracheal 
intubation conditions are inﬂ uenced by effects intrinsic to 
the hypnotic agent used in anesthesia. 
Etomidate, due to its hemodynamic proﬁ le and ability 
to maintain the degree of muscle perfusion, may contribute 
to a shorter latency of NDNMB 5. Our data showed that in all 
patients of both groups, the dose of atracurium (0.1 mg.kg-1) 
provided excellent laryngoscopy, with vocal cords comple-
tely relaxed. However, regarding clinical conditions for 
intubation, statistical analysis showed signiﬁ cant difference 
between groups, which may be attributed to the occurrence 
of vigorous cough in 47% of patients in Group II.
Propofol has been widely used as inducing agent, with 
some advantages over other hypnotics, such as etomidate 
and thiopental 13-16. The lower incidence of cough seen in 
the propofol group (two patients with mild cough) compa-
red to the etomidate group (vigorous cough in 14 patients) 
may be due to the greater depressant action of propofol on 
pharyngeal-laryngeal reﬂ exes 15,17-18. 
Propofol is able to decrease the reactivity of larynx 
and pharynx muscle tone and enable tracheal intubation 
without neuromuscular blockers 8,13,16-20. However, there are 
no reports in literature concerning its direct action on vocal 
cords. In vitro experiments showed that propofol at doses 
similar to those clinically used acts on the neuromuscular 
junction and reduces the channel open time of the muscle 
nicotinic receptors 6,7.
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Excellent and good scores are considered indicative of 
clinically acceptable conditions for tracheal intubation, but it 
depends on the skill of the professional performing tracheal 
intubation, depth of anesthesia, and degree of neuromuscular 
block 1,11. Thus, it is difﬁ cult to assess the pharmacodynamic 
properties of neuromuscular blockers considering only the in-
tubation conditions. Furthermore, it is important to note that 
when evaluating tracheal intubation, monitoring the adductor 
pollicis is questioned, as this muscle sensitivity to NDNMB is 
not parallel to that of muscles involved in laryngoscopy and 
tracheal intubation 21. Therefore, in this study we adopted the 
guidelines recommended by Fuchs-Buder et al. 1 to avoid 
factors that might interfere with neuromuscular block and to 
allow the adequate assessment of cisatracurium pharmacody-
namic characteristics. 
We assessed onset of action using acceleromyograhpy, 
considering a reduction of ≥ 95% in the response ampli-
tude of the adductor pollicis to isolated stimuli, time at 
which we performed laryngoscopy and tracheal intubation 
maneuvers.
Factors related to neuromuscular block monitoring also 
interfere with the blockade time 1,22. Experimental studies 
have shown that the onset of action of NDNMB is inversely 
proportional to the times for muscle response stabilization 
and stimulus frequency, as both periods are shorter and gre-
ater during stabilization and stimulus frequency is applied 
to achieve the response prior to NMB administration 1,23,24. 
The most likely explanation is that the series of contrac-
tions induced by nerve stimulation when maintained for 
a prolonged time increases muscle blood ﬂ ow and results 
in higher drug amount in the stimulated muscle. Another 
explanation is that the high frequency stimulation may lead 
to neurotransmitter depletion at the stimulation site, with 
consequent shortening of latency and increased degree of 
neuromuscular block 25,26. 
In this study, the onset of action of cisatracurium was sig-
niﬁ cantly lower in the propofol group than in the etomidate 
group (86.6 ± 14.3 vs 116, 9 ±  11.6 s). These results differ 
from those described by Bluestein et al. 11, who evaluated 
the effects of propofol as a hypnotic agent and cisatracurium 
at varying doses and different times for tracheal intubation. 
The authors reported that cisatracurium (0.1 mg.kg-1) had 
an onset of action of 4.6 minutes, and tracheal intubation 
conditions after 2 minutes of injection of NMB were good 
or excellent in 89% of patients. The use of higher doses of 
cisatracurium (equal to 3 or 4 ED95) increased this percen-
tage to 100% 1.5 min after NMB, and the onset of action 
was also shortened to 3.4 and 2.8 minutes with 3-4 ED95, 
respectively. 
Large doses of NMB (>2ED95) may be used to reduce the 
time of onset of neuromuscular blockers and obtain rapid 
muscle relaxation for tracheal intubation. However, it has 
drawbacks, such as a greater risk of cardiovascular effects, 
besides prolonged blockade11,27,28. 
Although one of the adverse effects of propofol is reduced 
cardiac index and systemic vascular resistance with conse-
quent hypotension29, there were no signiﬁ cant changes in the 
hemodynamic parameters of both groups in the present study 
that could have inﬂ uenced the neuromuscular block.
We conclude that the neuromuscular block with cisatra-
curium was faster and tracheal intubation conditions were 
better in patients receiving propofol compared to those 
receiving etomidate.
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